tetano
Editor, Senior Moderator
J Clin Immunol
. 2022 Aug 17.
doi: 10.1007/s10875-022-01350-1. Online ahead of print.
Anaphylaxis to SARS-CoV-2 Vaccines in the Setting of a Nationwide Passive Epidemiological Surveillance Program
Carla Toledo-Salinas[SUP] 1 [/SUP], Selma Cecilia Scheffler-Mendoza[SUP] 2 [/SUP], Lina Maria Castano-Jaramillo[SUP] 3 [/SUP], José Antonio Ortega-Martell[SUP] 4 [/SUP], Blanca Estela Del Rio-Navarro[SUP] 5 [/SUP], Ana María Santibáñez-Copado[SUP] 6 [/SUP], José Luis Díaz-Ortega[SUP] 6 [/SUP], Raúl Baptista-Rosas[SUP] 7 8 [/SUP], Paulina Sánchez-Novoa[SUP] 9 [/SUP], Miguel García-Grimshaw[SUP] 10 11 [/SUP], Sergio Iván Valdés-Ferrer[SUP] 10 12 [/SUP], Gustavo Reyes-Terán[SUP] 1 [/SUP], David Alejandro Mendoza-Hernández[SUP] 13 [/SUP]
Affiliations
Abstract
Background: Information on anaphylaxis among recipients of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains scarce.
Objective: To identify the observed incidence of anaphylaxis in recipients of different anti-SARS-CoV-2 vaccines.
Methods: A nationwide observational study among recipients of 61,414,803 doses of seven different anti-SARS-CoV-2 vaccines, describing the incidence and characteristics of adult patients (age ≥ 18 years) who developed anaphylaxis as an adverse event following immunization (AEFI) against SARS-CoV-2 vaccines between December 24, 2020, and October 15, 2021, in Mexico.
Results: Sixty-six patients developed anaphylaxis as an AEFI, for an overall observed incidence of 1.07 cases per 1,000,000 (95% CI 0.84-1.37) administered doses. Eighty-six percent of the patients were female, consistent with previous reports of AEFI to COVID-19 vaccines. mRNA-based vaccine recipients had the highest frequency of anaphylaxis, followed by adenovirus-vectored vaccines and inactivated virus recipients, with an observed incidence of 2.5, 0.7, and 0.2 cases per 1,000,000 doses administered, respectively. Only 46% of the patients received correct treatment with epinephrine as the first-line treatment through the appropriate route and dose. We detected one case of anaphylactic reaction-related death occurring 5 min following immunization with ChAdOx1 nCov-19 for a mortality rate of 1.5% among those who developed this AEFI.
Conclusions: In our population, anaphylactic reactions were infrequent. Our study provides further evidence supporting the security of these newly developed vaccines.
Keywords: Anaphylaxis; COVID-19 vaccines; SARS-CoV-2 vaccines; Vaccine anaphylaxis; Vaccine safety.
. 2022 Aug 17.
doi: 10.1007/s10875-022-01350-1. Online ahead of print.
Anaphylaxis to SARS-CoV-2 Vaccines in the Setting of a Nationwide Passive Epidemiological Surveillance Program
Carla Toledo-Salinas[SUP] 1 [/SUP], Selma Cecilia Scheffler-Mendoza[SUP] 2 [/SUP], Lina Maria Castano-Jaramillo[SUP] 3 [/SUP], José Antonio Ortega-Martell[SUP] 4 [/SUP], Blanca Estela Del Rio-Navarro[SUP] 5 [/SUP], Ana María Santibáñez-Copado[SUP] 6 [/SUP], José Luis Díaz-Ortega[SUP] 6 [/SUP], Raúl Baptista-Rosas[SUP] 7 8 [/SUP], Paulina Sánchez-Novoa[SUP] 9 [/SUP], Miguel García-Grimshaw[SUP] 10 11 [/SUP], Sergio Iván Valdés-Ferrer[SUP] 10 12 [/SUP], Gustavo Reyes-Terán[SUP] 1 [/SUP], David Alejandro Mendoza-Hernández[SUP] 13 [/SUP]
Affiliations
- PMID: 35976470
- DOI: 10.1007/s10875-022-01350-1
Abstract
Background: Information on anaphylaxis among recipients of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains scarce.
Objective: To identify the observed incidence of anaphylaxis in recipients of different anti-SARS-CoV-2 vaccines.
Methods: A nationwide observational study among recipients of 61,414,803 doses of seven different anti-SARS-CoV-2 vaccines, describing the incidence and characteristics of adult patients (age ≥ 18 years) who developed anaphylaxis as an adverse event following immunization (AEFI) against SARS-CoV-2 vaccines between December 24, 2020, and October 15, 2021, in Mexico.
Results: Sixty-six patients developed anaphylaxis as an AEFI, for an overall observed incidence of 1.07 cases per 1,000,000 (95% CI 0.84-1.37) administered doses. Eighty-six percent of the patients were female, consistent with previous reports of AEFI to COVID-19 vaccines. mRNA-based vaccine recipients had the highest frequency of anaphylaxis, followed by adenovirus-vectored vaccines and inactivated virus recipients, with an observed incidence of 2.5, 0.7, and 0.2 cases per 1,000,000 doses administered, respectively. Only 46% of the patients received correct treatment with epinephrine as the first-line treatment through the appropriate route and dose. We detected one case of anaphylactic reaction-related death occurring 5 min following immunization with ChAdOx1 nCov-19 for a mortality rate of 1.5% among those who developed this AEFI.
Conclusions: In our population, anaphylactic reactions were infrequent. Our study provides further evidence supporting the security of these newly developed vaccines.
Keywords: Anaphylaxis; COVID-19 vaccines; SARS-CoV-2 vaccines; Vaccine anaphylaxis; Vaccine safety.